 |
Fluvastatin and
bezafibrate, alone and in combination, were evaluated for their effects on fibrinogen,
plasminogen activator inhibitor 1 (PAI-1), and CRP in 333 patients with hyperlipidemia
(LDL-C 135–250 mg/dL, triglyceride 180–400 mg/dL) and stable angina, prior myocardial
infarction, or coronary revascularization. Patients were randomized to receive fluvastatin
40 mg (not shown), bezafibrate 400 mg, bezafibrate 400 mg + fluvastatin 20 mg, or
bezafibrate 400 mg + fluvastatin 40 mg for 24 weeks. Plasma fibrinogen was significantly
decreased by 9%, 14%, and 16% in the respective bezafibrate treatment groups. PAI-1 and
CRP levels did not change with any of the treatment regimens. Reference:
Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R,
on behalf of the FACT study centers. Effects of fluvastatin and bezafibrate combination on
plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in
coronary artery disease patients with mixed hyperlipidaemia (FACT study). Thromb Haemost
2000;83:549-553.
Web
site |
